Literature DB >> 15942703

Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients.

Umesh A Badrising1, Marion L C Maat-Schieman, Johannes C van Houwelingen, Peter A van Doorn, Sjoerd G van Duinen, Baziel G M van Engelen, Carin G Faber, Jessica E Hoogendijk, Aeiko E de Jager, Peter J Koehler, Marianne de Visser, Jan J G M Verschuuren, Axel R Wintzen.   

Abstract

The clinical features of inclusion body myositis (IBM) were of minor importance in the design of consensus diagnostic criteria, mainly because of controversial views on the specificity of signs and symptoms, although some authors reported "typical" signs. To re-assess the clinical spectrum of IBM, a single investigator using a standard protocol studied a cohort of 64 patients cross-sectionally. Symptom onset was before the age of 50 years in 20% of cases. Only a few patients (14 %) started with weakness other than that of quadriceps, finger flexor or pharyngeal muscles. The sequence of power loss was erratic, but onset of symptoms with quadriceps weakness predicted an earlier onset of dysphagia in older patients (> or = 56 years) compared with younger ones (< 56 years) (p = 0.02). Despite widespread weakness patients had favourable scores on three commonly used function scales and they kept their employment. Complete wheel-chair dependency was rare (3 %). A dominant characteristic was the anatomical distribution of afflicted muscles: ventral extremity muscle groups were more affected than dorsal muscle groups and girdle muscles were least affected, the latter preserving postural stability. Ankylosis, especially in extension of the fingers,was frequently present. Together with the sparing of intrinsic hand muscles it was helpful in the preservation of many skillful movements. IBM has a unique distribution of muscle weakness. Ankylotic contractures are common. We feel that their joint impact on daily functioning is characteristic for the disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15942703     DOI: 10.1007/s00415-005-0884-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  21 in total

1.  Inclusion body myositis in Connecticut: observations in 35 patients during an 8-year period.

Authors:  K J Felice; W A North
Journal:  Medicine (Baltimore)       Date:  2001-09       Impact factor: 1.889

2.  Patterns of muscle involvement in inclusion body myositis: clinical and magnetic resonance imaging study.

Authors:  B A Phillips; L A Cala; G W Thickbroom; A Melsom; P J Zilko; F L Mastaglia
Journal:  Muscle Nerve       Date:  2001-11       Impact factor: 3.217

3.  Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo.

Authors:  Umesh A Badrising; Marion L C Maat-Schieman; Michel D Ferrari; Aeilko H Zwinderman; Judith A M Wessels; Ferdinand C Breedveld; Pieter A van Doorn; Baziel G M van Engelen; Jessica E Hoogendijk; Chris J Höweler; Aeiko E de Jager; Frans G I Jennekens; Peter J Koehler; Marianne de Visser; Alain Viddeleer; Jan J Verschuuren; Axel R Wintzen
Journal:  Ann Neurol       Date:  2002-03       Impact factor: 10.422

4.  Inclusion body myositis: analysis of 32 cases.

Authors:  M E Sayers; S M Chou; L H Calabrese
Journal:  J Rheumatol       Date:  1992-09       Impact factor: 4.666

5.  FUNCTIONAL EVALUATION: THE BARTHEL INDEX.

Authors:  F I MAHONEY; D W BARTHEL
Journal:  Md State Med J       Date:  1965-02

6.  The Rivermead Mobility Index: a further development of the Rivermead Motor Assessment.

Authors:  F M Collen; D T Wade; G F Robb; C M Bradshaw
Journal:  Int Disabil Stud       Date:  1991 Apr-Jun

7.  Further observations on forearm flexor weakness in inclusion body myositis.

Authors:  K J Felice; G M Relva; S R Conway
Journal:  Muscle Nerve       Date:  1998-05       Impact factor: 3.217

8.  Disease progression in sporadic inclusion body myositis: observations in 78 patients.

Authors:  A Peng; B M Koffman; J D Malley; M C Dalakas
Journal:  Neurology       Date:  2000-07-25       Impact factor: 9.910

Review 9.  Inclusion body myositis and myopathies.

Authors:  R C Griggs; V Askanas; S DiMauro; A Engel; G Karpati; J R Mendell; L P Rowland
Journal:  Ann Neurol       Date:  1995-11       Impact factor: 10.422

10.  Inclusion body myositis. Observations in 40 patients.

Authors:  B P Lotz; A G Engel; H Nishino; J C Stevens; W J Litchy
Journal:  Brain       Date:  1989-06       Impact factor: 13.501

View more
  22 in total

1.  Immunohistochemical and ultrastructural analysis of sporadic inclusion body myositis: a case series.

Authors:  Katarzyna Haczkiewicz; Agata Sebastian; Aleksandra Piotrowska; Maria Misterska-Skóra; Agnieszka Hałoń; Marta Skoczyńska; Maciej Sebastian; Piotr Wiland; Piotr Dzięgiel; Marzenna Podhorska-Okołów
Journal:  Rheumatol Int       Date:  2018-12-08       Impact factor: 2.631

Review 2.  Inclusion body myositis.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Neurol Clin       Date:  2014-06-06       Impact factor: 3.806

3.  Follistatin gene delivery enhances muscle growth and strength in nonhuman primates.

Authors:  Janaiah Kota; Chalonda R Handy; Amanda M Haidet; Chrystal L Montgomery; Amy Eagle; Louise R Rodino-Klapac; Danielle Tucker; Christopher J Shilling; Walter R Therlfall; Christopher M Walker; Steven E Weisbrode; Paul M L Janssen; K Reed Clark; Zarife Sahenk; Jerry R Mendell; Brian K Kaspar
Journal:  Sci Transl Med       Date:  2009-11-11       Impact factor: 17.956

4.  Dysphagia in inflammatory myopathy: self-report, incidence, and prevalence.

Authors:  Kylie Patricia Mulcahy; Patricia Claire Langdon; Francis Mastaglia
Journal:  Dysphagia       Date:  2011-03-27       Impact factor: 3.438

5.  Demographic and clinical features of inclusion body myositis in North America.

Authors:  A David Paltiel; Einar Ingvarsson; Donald K K Lee; Richard L Leff; Richard J Nowak; Kurt D Petschke; Seth Richards-Shubik; Ange Zhou; Martin Shubik; Kevin C O'Connor
Journal:  Muscle Nerve       Date:  2015-02-17       Impact factor: 3.217

Review 6.  Inclusion body myositis.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Curr Neurol Neurosci Rep       Date:  2013-01       Impact factor: 5.081

Review 7.  Inclusion body myositis.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Semin Neurol       Date:  2012-11-01       Impact factor: 3.420

Review 8.  Inclusion body myositis: a view from the Caenorhabditis elegans muscle.

Authors:  Daniela L Rebolledo; Alicia N Minniti; Paula M Grez; Ricardo Fadic; Rebecca Kohn; Nibaldo C Inestrosa
Journal:  Mol Neurobiol       Date:  2008-09-05       Impact factor: 5.590

9.  Detecting dysphagia in inclusion body myositis.

Authors:  F M Cox; J J Verschuuren; B M Verbist; E H Niks; A R Wintzen; U A Badrising
Journal:  J Neurol       Date:  2009-07-15       Impact factor: 4.849

10.  The heart in sporadic inclusion body myositis: a study in 51 patients.

Authors:  Fieke M Cox; Victoria Delgado; Jan J Verschuuren; Bart E Ballieux; Jeroen J Bax; Axel R Wintzen; Umesh A Badrising
Journal:  J Neurol       Date:  2009-10-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.